FindTrial
Sign In

MP-424

DRUG8 trials

Sponsors

Tibotec BVBA, Tanabe Pharma Corporation

Conditions

Chronic Hepatitis CChronic Hepatitis C (CHC)Chronic Hepatitis C(CHC)Hepatitis CHepatitis C infection MedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis C

Phase 1

Clinical Pharmacology Study of MP-424
CompletedNCT01766167
Tanabe Pharma CorporationChronic Hepatitis C
Start: 2013-02-28End: 2013-04-30Updated: 2017-01-26

Phase 3

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
CompletedNCT00780416
Tanabe Pharma CorporationHepatitis C
Start: 2008-11-30End: 2010-08-31Updated: 2026-01-06
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
CompletedNCT00780910
Tanabe Pharma CorporationChronic Hepatitis C
Start: 2008-11-30End: 2010-10-31Updated: 2026-01-06
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
CompletedNCT00781274
Tanabe Pharma CorporationHepatitis C
Start: 2008-12-31End: 2010-07-31Updated: 2026-01-06
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
CompletedNCT01753557
Tanabe Pharma CorporationChronic Hepatitis C (CHC)
Start: 2012-12-31End: 2014-11-30Updated: 2026-01-06
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
CompletedNCT01753570
Tanabe Pharma CorporationChronic Hepatitis C(CHC)
Start: 2012-12-31End: 2015-10-31Updated: 2026-01-06

Unknown Phase

A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2b (PegIntron®) and ribavirin (Rebetol®) in treatment naïve subjects with chronic genytype 1 hepatitis C infection.
Active, not recruitingEUCTR2007-001044-44-BE
Tibotec BVBAHepatitis C infection MedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis C
Start: 2007-08-01Target: 160Updated: 2012-04-18
A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection
Active, not recruitingEUCTR2007-002920-14-GB
Tibotec BVBAHepatitis C infection MedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis C
Start: 2007-11-14Target: 48Updated: 2012-03-19